Intellia Therapeutics Leads Gene Editing Stock Rally

Intellia Therapeutics (NOW) – Get report led a rally in gene editing stocks on Wednesday as biotech soared on the results of a recent positive clinical trial and stock price increases from Wall Street analysts.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top